StreetAlpha.app
Home › Stocks › IMVT

Immunovant, Inc. (IMVT)

Healthcare
$33.21
▼ −0.21%
LAST CLOSE · NOV 17

Immunovant develops IMVT-1402, an experimental antibody treatment for autoimmune diseases driven by harmful IgG antibodies. It last closed at $33.21 on Nov 17, down 0.21% on the day. IMVT reports earnings on Fri, Feb 5, 2027. The average 12-month price target from 2 analysts is $40.00 (+20.4% from the last close), with a high of $47.00 and a low of $33.00. Over the past 90 days StreetAlpha recorded 2 whale options trades in IMVT, 50% of them bullish and 50% bearish.

AI Auto Pilots
Is IMVT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$509.0M
EPS (diluted)
−$2.56
Valuation
Market cap
$6.9B
206.9M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$722.3M
At Sep 30
Shareholder equity
$656.9M
Shares outstanding
206.9M
At Nov 3
Fiscal year endsMarch
ExchangeNasdaq
Financials history
FY2022: −$156.7M−$156.7MFY2022FY2023: −$211.0M−$211.0MFY2023FY2024: −$259.3M−$259.3MFY2024FY2025: −$413.8M−$413.8MFY2025FY2026: −$505.6M−$505.6MFY2026

From IMVT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Feb 5
2027 · Time not announced
Consensus EPS forecast
-$0.68
 
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
1 Buy · 1 Hold
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy · 1 Hold
2firms
1 Buy1 Hold0 Sell
Only 2 firms rated IMVT in the past 90 days, not enough for a consensus
Average 12-month target
$40.00
▲ 20.4% upside

Based on 2 analysts who set a price target on IMVT in the past 90 days. The average target is $40.00, with a high of $47.00 and a low of $33.00, compared with the last close of $33.21.

Low $33.00Avg $40.00High $47.00
Blue marker: last close $33.21
Highest target$47.00
Average target$40.00
Lowest target$33.00
Latest rating changes
Truist SecuritiesTarget raised
Nov 10Hold$30 → $33
Wells FargoMaintained
Nov 10Buy$47
JP MorganMaintained
Aug 4Buy$50
CitigroupMaintained
Jun 30Buy$61
GuggenheimMaintained
May 26Buy$62
DateFirmActionRatingPrice target
Nov 10Truist SecuritiesTarget raisedHold$30 → $33
Nov 10Wells FargoMaintainedBuy$47
Aug 4JP MorganMaintainedBuy$50
Jun 30CitigroupMaintainedBuy$61
May 26GuggenheimMaintainedBuy$62
Loading…

Technical Analysis

IMVT · as of the Nov 17 close · updated after every close
Uptrend

The stock is 6% above its 20 day and 2% above its 50 day average. It is 2% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 54). The nearest support is the Pivot at $33.16, and the nearest resistance the Pivot R1 at $33.87.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 4.7%/day
Key levels
$45.4252 week high+36.8%
$36.42100 day average+9.7%
$34.60Swing high (Oct 1)+4.2%
$33.87Pivot R1+2.0%
$33.21Last close
$33.16Pivot−0.2%
$32.50Pivot S1−2.1%
$32.45Swing low (Sep 29)−2.3%
$32.42200 day average−2.4%
$32.3950 day average−2.5%
$31.0520 day average−6.5%
$21.8652 week low−34.2%
Indicators
RSI (14)54.35Middle of its rangeNeutral
MACD0.79Above its signal lineBullish
Stochastic57.5Middle of its rangeNeutral
ADX (14)30.6Trending up
Williams %R-46.3Oversold below −80, overbought above −20Neutral
CCI (20)54.4Oversold below −100, overbought above 100Neutral
Rate of change+14.4%Change over 10 sessionsBullish
ATR (14)$1.56Typical daily range, 4.7% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Above
What happened before, for IMVT

What happened before

See how IMVT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IMVT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IMVT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
1
50%
Bearish
1
50%
Date span
Oct 8 – Oct 8
Loading…

See today’s whale options flow across the market →

IMVT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●116 buying vs 102 selling
  • ▼Held by funds -0.7 pts
  • ▲Funds holding +7
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding233226+3.1%
In funds' top 1087+14.3%
Held by funds52.7%53.4%−0.7 pts
New / increased36 / 8037 / 74+4.5%
Reduced / sold out73 / 2979 / 24−1.0%
Put/call ratio0.000.00−70.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IMVT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMVT is in one of them and how their past IMVT trades turned out.

IMVT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IMVT in an article yet. Here's the latest on the wider market.

About Immunovant

Immunovant is a drug developer focused on autoimmune diseases, based in Durham, North Carolina. Its main product candidate, IMVT-1402, is an antibody designed to block the FcRn protein and lower levels of harmful IgG antibodies. The company is testing the candidate in conditions such as Graves' disease, myasthenia gravis and rheumatoid arthritis. The treatment is being developed for injection that patients can give themselves. Its intended patients are people living with autoimmune diseases driven by IgG antibodies.

Headquarters
Durham, NC